Compare Stocks: EGRX, SCYX, GRCE, and SCLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$0.90 -30.0%	$0.62	$0.00 ▼ $3.00	$11.69M	0.83	7,847 shs	294 shs
GRCE Grace Therapeutics	$2.12 -0.9%	$2.18	$1.79 ▼ $5.18	$45.02M	0.44	138,985 shs	184,659 shs
SCLX Scilex	$5.10 -4.7%	$6.14	$4.20 ▼ $30.90	$45.44M	1.65	32,925 shs	8,702 shs
SCYX SCYNEXIS	$4.64 -4.5%	$4.78	$3.53 ▼ $9.12	$48.35M	1.11	67,494 shs	65,033 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	0.00%	-29.96%	+69.81%	+50.00%	-73.29%
GRCE Grace Therapeutics	-0.93%	-0.93%	-2.75%	-10.55%	-31.83%
SCLX Scilex	-4.67%	-1.35%	-9.89%	-28.07%	-82.29%
SCYX SCYNEXIS	-4.53%	+12.90%	-11.79%	+21.78%	-45.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$0.90 -30.0%	$0.62	$0.00 ▼ $3.00	$11.69M	0.83	7,847 shs	294 shs
GRCE Grace Therapeutics	$2.12 -0.9%	$2.18	$1.79 ▼ $5.18	$45.02M	0.44	138,985 shs	184,659 shs
SCLX Scilex	$5.10 -4.7%	$6.14	$4.20 ▼ $30.90	$45.44M	1.65	32,925 shs	8,702 shs
SCYX SCYNEXIS	$4.64 -4.5%	$4.78	$3.53 ▼ $9.12	$48.35M	1.11	67,494 shs	65,033 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	0.00%	-29.96%	+69.81%	+50.00%	-73.29%
GRCE Grace Therapeutics	-0.93%	-0.93%	-2.75%	-10.55%	-31.83%
SCLX Scilex	-4.67%	-1.35%	-9.89%	-28.07%	-82.29%
SCYX SCYNEXIS	-4.53%	+12.90%	-11.79%	+21.78%	-45.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
GRCE Grace Therapeutics	2.00	Hold	$6.00	183.02% Upside
SCLX Scilex	1.00	Sell	N/A	N/A
SCYX SCYNEXIS	2.33	Hold	$33.00	611.21% Upside

Current Analyst Ratings Breakdown

Latest EGRX, SCYX, GRCE, and SCLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	SCLX Scilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	SCLX Scilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EGRX Eagle Pharmaceuticals	$257.55M	0.05	$2.25 per share	0.40	N/A	∞
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$3.99 per share	N/A
SCLX Scilex	$30.25M	1.43	N/A	N/A	($24.94) per share	-0.20
SCYX SCYNEXIS	$20.60M	2.24	N/A	N/A	$9.07 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.76	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
SCLX Scilex	-$358.73M	-$49.70	N/A	N/A	N/A	-1,414.57%	N/A	-147.00%	12/2/2026 (Estimated)
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	-41.79%	-44.15%	-32.61%	11/4/2026 (Estimated)

Latest EGRX, SCYX, GRCE, and SCLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/14/2026	Q2 2026	SCLX Scilex	-$0.1813	-$16.65	-$16.4687	-$16.65	$16.00 million	$7.64 million
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	11.47	11.47
SCLX Scilex	N/A	0.07	0.06
SCYX SCYNEXIS	N/A	9.65	9.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EGRX Eagle Pharmaceuticals	85.36%
GRCE Grace Therapeutics	6.08%
SCLX Scilex	69.67%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
EGRX Eagle Pharmaceuticals	28.90%
GRCE Grace Therapeutics	10.84%
SCLX Scilex	4.50%
SCYX SCYNEXIS	4.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
GRCE Grace Therapeutics	5	21.04 million	18.76 million	N/A
SCLX Scilex	34	8.49 million	8.11 million	No Data
SCYX SCYNEXIS	29	9.95 million	9.54 million	Optionable

EGRX, SCYX, GRCE, and SCLX Headlines

Recent News About These Companies

SCYNEXIS (NASDAQ:SCYX) Shares Pass Above 50-Day Moving Average - Time to Sell?

September 23 at 4:01 AM | americanbankingnews.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

September 22 at 11:14 PM | markets.businessinsider.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

September 22 at 8:00 AM | globenewswire.com

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

September 15, 2026 | globenewswire.com

SCYNEXIS Names Sanjay Subramanian as CFO

September 10, 2026 | finance.yahoo.com

Scynexis Names Sanjay Subramanian CFO

September 10, 2026 | rttnews.com

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average - Here's What Happened

September 9, 2026 | marketbeat.com

SCYNEXIS to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average - Should You Sell?

September 1, 2026 | marketbeat.com

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026 | globenewswire.com

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | tmcnet.com

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 30, 2026 | globenewswire.com

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

June 26, 2026 | tipranks.com

SCYNEXIS Inc.

June 24, 2026 | marketwatch.com

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026 | globenewswire.com

SCYNEXIS (SCYX) price target increased by 20.73% to 4.28

May 14, 2026 | msn.com

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026 | globenewswire.com

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026 | globenewswire.com

SCYNEXIS Raises $40 Million in Strategic Private Placement

April 19, 2026 | theglobeandmail.com

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

March 31, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, SCYX, GRCE, and SCLX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

$0.90 -0.39 (-29.96%)

As of 09/23/2026 02:52 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Grace Therapeutics NASDAQ:GRCE

$2.12 -0.02 (-0.93%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.20 +0.08 (+3.63%)

As of 09/23/2026 07:57 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Scilex NASDAQ:SCLX

$5.10 -0.25 (-4.67%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$5.12 +0.02 (+0.29%)

As of 09/23/2026 07:30 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

SCYNEXIS NASDAQ:SCYX

$4.64 -0.22 (-4.53%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.71 +0.07 (+1.51%)

As of 09/23/2026 07:59 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, SCYX, GRCE, and SCLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, SCYX, GRCE, and SCLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, SCYX, GRCE, and SCLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, SCYX, GRCE, and SCLX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

Grace Therapeutics NASDAQ:GRCE

Scilex NASDAQ:SCLX

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, SCYX, GRCE, and SCLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, SCYX, GRCE, and SCLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, SCYX, GRCE, and SCLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, SCYX, GRCE, and SCLX Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

Grace Therapeutics NASDAQ:GRCE

Scilex NASDAQ:SCLX

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools